ospitalized patients are at a higher risk of stroke than the general population.
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hospitals. Approximately 1000 hospitals are sampled each year and all the inpatient admissions from the sampled hospitals are included in NIS. It contains >100 clinical and nonclinical discharge level variables including primary and secondary diagnoses, in-hospital procedures including the day of the procedure from the admission, demographic and hospital characteristics, and discharge outcomes. Detailed information regarding the content and the methodology of NIS is available at the Agency for Healthcare Research and Quality website http://www.hcup-us.ahrq.gov/nisoverview.jsp (accessed December 1, 2012).
13
Case Selection Figure 1 shows the case selection flowchart of the study. Ascertainment of all diagnoses and procedures was made by using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes recorded at discharge ( Table I in the online-only Data Supplement). Acute ischemic stroke cases, aged >18 years, were selected using ICD-9 codes 433.x1, 434.x1, or 436, [13] [14] [15] [16] and thrombolytic infusion was ascertained by procedure code 99.10. 17, 18 As NIS database lacks explicit IHS variable, cases were classified as OHS if thrombolytic treatment was administered on the day of hospitalization and as IHS if thrombolytic treatment was given on the second day of hospitalization or later. Cases with missing information regarding the thrombolysis day were excluded from the study. Patients transferred from another hospital were also excluded because they may have developed symptoms while in the previous hospital but received thrombolysis on the day of arrival to the current hospital. In addition, the cases with acute myocardial infarction or pulmonary embolism and those on dialysis (with possibly clotted access) were excluded to avoid uncertainty of indication for thrombolytic infusion.
The Elixhauser comorbidities, 19 modified to create a weighted numeric score as recommended by van Walraven et al, 20 were used to quantify patients' comorbidity profiles. The Elixhauser comorbidities have been validated for prognostication in studies using administrative datasets with ICD-9 codes. [21] [22] [23] The primary outcomes of the study were favorable discharge disposition defined as discharge to home/self-care and inpatient mortality. Secondary outcomes were symptomatic or asymptomatic intracerebral hemorrhage (ICH), gastrointestinal bleeding, tracheostomy, and gastrostomy tube placement. Endovascular treatment was ascertained by the performance of invasive cerebral angiogram (ICD-9 procedure code 88.41) with thrombolytic infusion (99.10), and mechanical thrombectomy (39.74). 24, 25 We compared the outcomes of IHS and OHS among intravenous thrombolysis only and endovascular thrombolysis groups.
Statistical Analysis
Nonparametric Elixhauser Index was categorized into the following quartiles: (1) <5, (2) 5 to 7, (3) 8 to 14, and (4) >14. Missing ethnicity data (14.5%) were coded as missing information without any imputation. Comparisons were made by Pearson χ 2 for categorical variables. Mantel-Haenszel test was used to calculate unadjusted odds ratios (ORs). Outcomes were adjusted using multivariate logistic regression after controlling for age group, sex, ethnicity, hospital characteristics, such as bed-size, location/teaching status and region, and Elixhauser Index. Hosmer-Lemeshow test was used to assess goodness-of-fit of the regression models. All analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL) with statistical significance set at 0.05.
Results
Of the 11 750 thrombolysed ischemic strokes included in the study, 1020 (8.7%) were IHSs. Age and sex distributions between IHS and OHS cohorts were not significantly different. IHS was more common in large-sized and urban teaching hospitals and hospitals in the Northeast region of the United States ( Table 1) . Comparison of baseline characteristics and outcomes of cases with missing thrombolysis day (13.7%) with those with known thrombolysis day is shown in Table II in the online-only Data Supplement. The cases with missing thrombolysis day were more likely to be from the Midwest and large-sized urban teaching hospitals.
On univariate analysis, IHS had significantly higher Elixhauser Comorbidity Index compared with OHS. Dyslipidemia and hypertension were more common in OHS. IHSs were more likely to have atrial fibrillation, coronary artery disease, chronic kidney disease, congestive heart failure, coagulopathy, diabetes mellitus with chronic complications, metastatic cancer, and solid tumor without metastasis. In-hospital acute medical conditions associated with IHS were acute kidney injury, acute respiratory failure, cardiac arrest, deep venous thrombosis, pneumonia, sepsis, and urinary infection ( Figure 2 ). Univariate outcomes by endovascular treatment showed higher inpatient mortality and lower rate of favorable discharge among IHS treated with intravenous thrombolysis only and among IHS treated with endovascular treatment (Table 3 ). In the multivariate analysis, IHS was associated with lower rate of discharge to home/self-care (adjusted OR, 0.79; 95% CI, 0.67-0.93; P=0.005) and higher inpatient mortality (adjusted OR, 1.59; 95% CI, 1.32-1.92; P<0.001; Table 4 ). 
Discussion
Our data suggest that inpatient mortality is higher and favorable discharge disposition is lower in thrombolysed IHS compared with thrombolysed OHS. Previous studies have shown that IHSs are more likely to be embolic, resulting in more severe deficits at onset. 3, 7, 25, 26 Kimura et al 8 reported higher median National Institutes of Health Stroke Scale in IHS compared with OHS. These studies indicate that IHS represents more severe stroke cases with poorer expected outcomes with or without thrombolytic treatment. In addition, evaluation of the IHS patients may be delayed for various reasons, such as the use of sedative or paralytic medications, delirium, and complexities of hospital practice leading to longer inhospital delays among IHS, further contributing to the poor outcomes.
11,12
Although we did not find difference in age distribution between the 2 groups, Kimura et al 8 found that patients with IHS were older than OHS. As our study included only the patients treated with thrombolysis, this finding might suggest that elderly patients with IHS were preferentially excluded from thrombolytic treatment by the treating clinicians. We could not find previous reports comparing hospital characteristics between IHS and OHS. We found that the rate of thrombolysed IHS was higher in large-sized, urban teaching hospitals, a finding potentially indicative of greater adherence of academic institutions to evidence-based use of thrombolytic treatment irrespective of the in-hospital onset of the stroke. Vera et al 11 found higher comorbidities in patients with IHS. Similarly, in this study, IHS had significantly higher Elixhauser Comorbidity Index, which is associated with worse outcomes after stroke. 23 Similar to prior reports, 6, 8, 9, 12 IHS had higher rate of atrial fibrillation and lower rates of dyslipidemia and hypertension in our study. Of note, several comparisons in this study may have reached statistical significance with small absolute differences because of large sample size. Despite the presumed higher use of antiplatelet and antithrombotic treatment 12 and higher incidence of embolic stroke with more severe deficits and larger infarct size among IHS, the rate of the most feared complication of thrombolysis (ie, ICH) was not significantly different between the 2 groups, potentially implying relative safety of thrombolysis in IHS. The rate of all ICH in this study was lower than that in previous studies reporting symptomatic ICH 27, 28 likely because of underascertainment of hemorrhagic conversion of ischemic stroke using the only available ICD-9 code for intracerebral hemorrhage.
Higher use of endovascular treatment in IHS may be suggestive of more numbers of patients not eligible for systemic thrombolysis because of recent surgery or bleeding, or higher clot burden and, therefore, greater resistance to recanalization by intravenous thrombolysis alone in IHS. 29 The worse outcomes in the endovascular group may be because of selective endovascular treatment of patients with more severe deficits, delayed recognition of stroke, or poor response to systemic thrombolysis.
This study has several important limitations related to the administrative nature of the database. NIS database lacks information regarding symptom onset. Therefore, we used the day of thrombolysis in relation to the day of admission to define IHS indirectly. Although this definition is expected to identify a vast majority of IHS cases correctly, misclassification is possible. For instance, patients with IHS who developed the symptoms on the day of hospitalization and subsequently were given treatment on the same day are incorrectly classified as OHS. Similarly, OHS cases admitted before midnight and treated after midnight would be misclassified as IHS. NIS also lacks stroke severity measure, such as National Institutes of Health Stroke Scale, a strong predictor of the outcome, 30 thus limiting the adjusted analyses. NIS does not contain standard outcome measure, such as 3-month modified Rankin Scale, or pathogenic classification, such as Trial of Org 10172 in Acute Stroke Treatment subtype. However, discharge destination as a surrogate for functional status has been shown to have high predictive value for 3-and 12-month poststroke modified Rankin Scale. 31 Coding error is another potential source of bias. However, the ICD-9 codes used to select acute ischemic The ICD-9 procedure code 99.10 has the sensitivity of 55% to 70% and the specificity of 98% for thrombolytic treatment in stroke. [33] [34] [35] Therefore, underascertainment is possible but case identification is likely to be accurate. We were not able to differentiate symptomatic from asymptomatic ICH because of lack of clinical data in NIS. Finally, the differences in the geographic distribution and hospital characteristics of 
Conclusions
IHS comprises a significant subgroup of stroke with greater potential for thrombolytic treatment benefit as they avoid prehospital delays. However, IHS results in worse short-term outcomes when compared with OHS because of their coexistent medical illnesses and comorbidities. Despite IHS being a high-risk group for complications of thrombolytic treatment, the rate of ICH in IHS was comparable with that in OHS in our study, potentially indicating relative safety of thrombolysis in IHS. Prospective studies of thrombolytic therapy for IHS from clinical data source are needed to confirm our findings.
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